Regenerative Medicine » Designer Children Latest News

Organogenesis CEO Geoff MacKay Elected Chairman of MassBio Board of Directors

Mar 272012

CANTON, Mass., March 27, 2012 /PRNewswire/ –Today MassBio members elected Geoff MacKay, president & CEO of regenerative medicine leader Organogenesis Inc., as chairman of the board of directors at the 2012 MassBio Annual Meeting.

(Photo: http://photos.prnewswire.com/prnh/20120327/NE76866)

During this year’s meeting, MassBio members also elected three new board members: Caren Arnstein, senior vice president and Head of Communications for Genzyme, James Hoyes, President of EMD Serono, Inc., and David Lucchino, CEO of Semprus BioSciences. MacKay will serve a two-year term as board chair.

“Geoff has long been a champion and an advocate for the biotechnology industry in Massachusetts and we look forward to his vision for the future of the industry association,” Robert K. Coughlin, President & CEO of MassBio.

Mr. MacKay has served as president and CEO of Organogenesis since 2003 and provides significant global, commercial experience spanning the pharmaceutical and biotechnology sectors. He has held numerous leadership positions throughout his career, including in the areas of transplantation, immunology and tissue engineering, and specifically in the regenerative medicine field for the last decade.

“It is an honor to be elected to serve the country’s oldest biotech trade association, especially during a time of tremendous growth and change for the industry,” said MacKay. “Organogenesis, which was founded as an MIT spin-off, is a Massachusetts success story. Our company has benefitted throughout its development from the state’s biotech super-cluster, including the robust confluence of academia, skilled workforce, innovation and investment. During my term, I hope to bring the experiences of a fast-growing life sciences company, as well as the examples it can provide for the industry, to MassBio as it works to strengthen and build the biotech industry of the future.”

About MassBio

MassBio, a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry, is the nation’s oldest biotechnology trade association. Founded in 1985, MassBio is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing over 600 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and health care, MassBio works to advance policy and promote education, while providing member programs and events, industry information, and services.

For more information, visit the Massachusetts Pavilion at the 2012 BIO International Convention (# 137 on the Exhibit Floor) or the organization’s website at www.massbio.org.

About Organogenesis Inc.

Excerpt from:
Organogenesis CEO Geoff MacKay Elected Chairman of MassBio Board of Directors

Tengion Announces Significant Advances in Neo-Urinary Conduit™ and Neo-Kidney Augment™ Programs

Regenerative Medicine Comments Off

Mar 272012

WINSTON-SALEM, N.C., March 26, 2012 /PRNewswire/ –Tengion, Inc. (NASDAQ: TNGN – News), a leader in regenerative medicine, today announced that it has made significant advances in its two lead programs. A fourth patient was implanted in the last several weeks in the ongoing initial clinical trial of the Company’s lead product candidate, the Neo-Urinary Conduit. The Company also submitted a pre-Investigational New Drug (IND) filing to the U.S. Food and Drug Administration (FDA) for its lead preclinical program, the Neo-Kidney Augment. Tengion also announced its fourth quarter and full year 2011 financial results in a separate release issued today and will hold a conference call to discuss these updates today, March 26, 2012, at 5:00 p.m. EDT.

“The implanting of the Neo-Urinary Conduit into the fourth patient and the pre-IND filing for our Neo-Kidney Augment are significant achievements for Tengion and we are confident in our ability to execute on our ambitious objectives for these two programs going forward,” stated John L. Miclot, President and Chief Executive Officer of Tengion. “We have gained substantial knowledge and insight from the first three patients in the ongoing trial for the Neo-Urinary Conduit and we believe that the surgical modifications implemented for the fourth patient will improve outcomes for current and future patients in the trial. In addition, now that we have submitted a pre-IND filing to the FDA for the Neo-Kidney Augment, we are preparing a proposed clinical trial design and timeline to continue our progress toward establishing clinical proof of concept.”

Neo-Urinary Conduit Clinical Program UpdateTengion has now enrolled a fourth patient in the ongoing initial clinical trial of its lead product candidate, the Neo-Urinary Conduit, which is being evaluated in bladder cancer patients requiring a urinary diversion following bladder removal (cystectomy). The trial is designed to assess the safety and preliminary efficacy of the Neo-Urinary Conduit in up to 10 patients, as well as to translate the surgical procedure successfully used in preclinical animal models into clinical trials with human patients. The ongoing initial trial is being conducted at the University of Chicago Medical Center and at The Johns Hopkins Hospital in Baltimore, Maryland.

The goal set by the clinical investigators in this trial has been to optimize the surgical procedure and post-surgical care by incorporating the outcomes observed in each patient into the surgical approach for subsequent patients, as necessary. Data from the first three patients have allowed clinical investigators to make surgical modifications for the trial moving forward in an effort to address conduit patency and vascular supply. Complications that arose in the first three patients were resolved successfully and, following new surgeries to construct a urinary diversion using bowel tissue, all three patients have recovered well.

Upon implanting the fourth patient in the ongoing trial, Tengion and its clinical investigators believe they have translated the surgical technique, including the procedure to provide greater blood supply to the Neo-Urinary Conduit supporting regeneration of urinary tissue; the ureteral attachment to the Neo-Urinary Conduit using an established surgical procedure used in the current standard of care; and the procedure for the stoma incision and passage of the Neo-Urinary Conduit with its blood supply through the abdominal wall. The Company is also collaborating with post-operative care staff at the two trial sites to optimize stoma management for rapid patient recovery.

The Company plans to discuss with the Data Safety Monitoring Board a reduction in the timelines between future patient implants, which is currently 12 weeks. If granted and assuming appropriate safety data, the Company anticipates that it will complete implantation of up to 10 patients by the end of 2012.

Neo-Kidney Augment Preclinical Program UpdateTengion submitted a pre-IND filing to the FDA for its lead preclinical program, the Neo-Kidney Augment, one quarter ahead of schedule. The Neo-Kidney Augment is intended to prevent or delay the need for dialysis or kidney transplant by catalyzing the regeneration of functional kidney tissue in patients with advanced chronic kidney disease (CKD). Following the early submission of the pre-IND, Tengion’s Board of Directors has authorized the Company to aggressively pursue the development of its Neo-Kidney Augment program and will retain the full team of employees involved in the Neo-Kidney Augment program.

Tengion has scheduled a meeting with the FDA to discuss the Company’s proposed GLP animal study program to support an IND filing. Tengion is also exploring moving forward using the Advanced Therapy Medicinal Products (ATMP) pathway, an established regulatory route in Europe for advanced cell-based therapies. The Company expects to provide an update on its expectations for the clinical trial program in its first quarter 2012 financial results announcement in May.

About the Neo-Urinary ConduitThe Neo-Urinary Conduit is a combination of a patient’s own cells and bioabsorbable scaffold that is intended to catalyze regeneration of a native bladder tissue conduit, passively transporting urine from the ureters through a stoma, or hole in the abdomen, into a standard ostomy bag. Standard of care for patients requiring a non-continent urinary diversion uses bowel tissue to construct a conduit for urine to exit from the body. There are over 20,000 urinary diversions performed annually in the United States and Europe. These patients are at risk for complications associated with the use of bowel tissue, as well as for those associated with the surgery to harvest the bowel tissue. The Neo-Urinary Conduit is the only product currently in development that aims to avoid the use of bowel tissue.

About the Neo-Kidney AugmentThe Neo-Kidney Augment is intended to prevent or delay the need for dialysis or kidney transplant by catalyzing the regeneration of functional kidney tissue in patients with advanced chronic kidney disease (CKD). This increase in functional kidney mass could thereby delay or prevent the need for dialysis or kidney transplant in patients with end stage renal disease (ESRD). According to the United States Renal Data System, more than $27 billion in Medicare costs each year are attributable to patients with ESRD and ESRD is associated with an approximate 20% mortality rate per year, with the average life expectancy of a patient initiating dialysis of approximately four years. Tengion scientists have published and presented positive data on the effect of the Company’s Neo-Kidney Augment in four different preclinical models of CKD. Two of these preclinical models have been conducted for a sufficiently long period of time to demonstrate durability and an impact on survival.

Here is the original post:
Tengion Announces Significant Advances in Neo-Urinary Conduit™ and Neo-Kidney Augment™ Programs

Synthetic pasta-like objects are major chemistry advances for regenerative medicine

Regenerative Medicine Comments Off

Mar 272012

Medicine’s recipe for keeping older people active and functioning in their homes and workplaces – and healing younger people injured in catastrophic accidents – may include “noodle gels” and other lab-made invisible filaments that resemble uncooked spaghetti with nanoscale dimensions, a scientist said here today at the 243rd National Meeting & Exposition of the American Chemical Society (ACS). The world’s largest scientific society, ACS is meeting here this week with reports on more than 11,000 reports on new advances in science on its schedule.

Samuel I. Stupp, Ph.D., who presented an ACS plenary lecture, explained that the synthetic pasta-like objects actually are major chemistry advances for regenerative medicine that his research team has accomplished. Regenerative medicine is an emerging field that combines chemistry, biology and engineering. It focuses on the regeneration of tissues and organs for the human body, to repair or replace those damaged through illness, injury, aging or birth defects. Those tissues range from cartilage in joints damaged by arthritis to heart muscle scarred by a heart attack and nerves severed in auto accidents.

“A graying of the population is underway in industrialized countries,” Stupp said. “In the U.S., we have the ‘baby boom’ generation – 75 million people born between 1946 and 1964, who now are reaching their mid-60s. At the same time, people are living longer – into their 80s, 90s and even 100s. With that comes an expectation of a better quality of life. It’s also an economic issue because with lifespan rising, we’re going to have to think about how to provide healthcare and keep people functional for longer periods of time, perhaps to keep them in the workforce longer.”

Stupp explained that advances in regenerative medicine also hold promise to improve people’s lives at any age. For example, a young person could survive a car accident, but emerge with a spinal cord injury and be paralyzed. Also, cardiovascular disease and heart attacks are a leading cause of premature death around the world. Cartilage wears away and does not regenerate on its own in the body, leading to painful osteoarthritis. Some bones do not mend correctly. And the millions of people with diabetes face complications, including blocked blood vessels that result in an increased risk of heart attacks and limb amputations. Regenerative medical techniques could coax cells to grow and repair all of these types of damage, said Stupp, who is with Northwestern University. He is Board of Trustees Professor of Chemistry, Materials Science and Engineering, and Medicine and director of the Institute for BioNanotechnology in Medicine.

One type of spaghetti-like filament developed by Stupp’s team is a nanostructure of small bits of protein that glue themselves together spontaneously. These nanofilaments are so small that more than 50,000 would fit across the width of a human hair, and they can serve as smart scaffolds for many uses. For example, Stupp attached to these fibers signaling substances that mimic a powerful substance called VEGF that can promote the formation of new blood vessels. The VEGF-mimic caused new blood vessels to form in mice (stand-ins for humans) with blood vessel damage.

Go here to read the rest:
Synthetic pasta-like objects are major chemistry advances for regenerative medicine

'Noodle gels' or 'spaghetti highways' could become tools of regenerative medicine

Regenerative Medicine Comments Off

Mar 262012

Public release date: 25-Mar-2012 [ | E-mail | Share ]

Contact: Michael Bernstein m_bernstein@acs.org 619-525-6268 (March 23-28, San Diego Press Center) 202-872-6042

Michael Woods m_woods@acs.org 619-525-6268 (March 23-28, San Diego Press Center) 202-872-6293 American Chemical Society

SAN DIEGO, March 25, 2012 Medicine’s recipe for keeping older people active and functioning in their homes and workplaces and healing younger people injured in catastrophic accidents may include “noodle gels” and other lab-made invisible filaments that resemble uncooked spaghetti with nanoscale dimensions, a scientist said here today at the 243rd National Meeting & Exposition of the American Chemical Society (ACS). The world’s largest scientific society, ACS is meeting here this week with reports on more than 11,000 reports on new advances in science on its schedule.

“A graying of the population is underway in industrialized countries,” Stupp said. “In the U.S., we have the ‘baby boom’ generation 75 million people born between 1946 and 1964, who now are reaching their mid-60s. At the same time, people are living longer into their 80s, 90s and even 100s. With that comes an expectation of a better quality of life. It’s also an economic issue because with lifespan rising, we’re going to have to think about how to provide healthcare and keep people functional for longer periods of time, perhaps to keep them in the workforce longer.”

“When VEGF itself was used in clinical trials on humans, it didn’t work, despite a lot of laboratory research that suggested otherwise,” said Stupp. “The problem was that VEGF was quickly broken down in the body. The nanofilament scaffold, however, lasts in the body for weeks, which allows the VEGF-mimic more time to grow vessels.” Eventually, the nanofilaments break down and disappear, leaving only the new blood vessels behind.

In other research, his group developed so-called “noodle gels,” which are nanofibers that form long, noodle-like gels when they are heated, cooled and then squeezed out from a pipette (much like frosting from a piping bag) into salty water. These gels can be more than half an inch long and are visible with the naked eye.

Original post:
'Noodle gels' or 'spaghetti highways' could become tools of regenerative medicine

Soon, noodle gels 'may become tools of regenerative medicine'

Regenerative Medicine Comments Off

Mar 262012

Washington, Mar 26 (ANI): Medicine's recipe for keeping older people active and functioning in their homes and workplaces and healing younger people injured in catastrophic accidents may include “noodle gels” and other lab-made invisible filaments that resemble uncooked spaghetti with nanoscale dimensions, a scientist has claimed.

Continued here:
Soon, noodle gels 'may become tools of regenerative medicine'

Stem Cells and Regenerative Medicine for Cardiac Care by Dr. Victor Dzau - Video

Regenerative Medicine Comments Off

Mar 242012

22-03-2012 12:16 Dr. Victor Dzau is a physician and pioneering translational research scientist, and is widely recognized as one of the most influential medical leaders worldwide. He is currently the James B. Duke Professor of Medicine at Duke University and the President and CEO of Duke University Health System. Dr. Dzau’s groundbreaking research established the curent understanding of the renin-angiotensin system, which is now known to underlie a wide range of heart and blood vessel diseases, from hypertension to heart failure. His work led directly to the development of drugs that inhibit this system, that now represent the foundation of modern medical therapy for many cardiac disorders. Dr. Dzau continues to lead an innovative and productive reseach lab, pioneering innovative stem cell and genetic treatments for heart and blood vessel diseases. Dr. Dzau has received numerous honors for his contributions to research and medicine, including the 2011 Henry G. Friesen International Prize in Health Research.

Regenerative Medicine Science - Video

Regenerative Medicine Comments Off

Mar 242012

23-03-2012 13:00 Regenerative Medicine is a revolutionary medical approach that taps into the body’s innate ability to regenerate or heal itself. Organogenesis specializes in bringing this exciting new approach to patients today.

See more here:
Regenerative Medicine Science – Video

BioTime CEO Michael D. West to Present at 2012 Maxim Group Growth Conference

Regenerative Medicine Comments Off

Mar 222012

ALAMEDA, Calif.–(BUSINESS WIRE)–

BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer, Michael D. West, Ph.D., will present a corporate overview of BioTime and its subsidiaries with an update on recent developments at the 2012 Maxim Group Growth Conference on Monday, March 26, 2012, 11:00 a.m. EDT, at the Grand Hyatt in New York City. The presentation will be webcast and available online at the Investors section of the BioTime website at www.biotimeinc.com.

The 5th annual Maxim Group Growth Conference is designed to provide institutional clients with the opportunity to gain an in-depth perspective on the issues affecting the growth of presenting companies. The one-day event will feature more than 80 company presentations across six designated industry tracks including the healthcare and biotechnology sectors.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is developed through subsidiaries focused on specific fields of applications. BioTime develops and markets research products in the field of stem cells and regenerative medicine, including a wide array of proprietary ACTCellerate cell lines, culture media, and differentiation kits. BioTime’s wholly owned subsidiary ES Cell International Pte. Ltd. has produced clinical-grade human embryonic stem cell lines that were derived following principles of Good Manufacturing Practice and currently offers them for use in research. BioTime’s therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime’s majority owned subsidiary Cell Cure Neurosciences, Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. Cell Cure’s minority shareholder Teva Pharmaceutical Industries has an option to clinically develop and commercialize Cell Cure’s OpRegen retinal cell product for use in the treatment of age-related macular degeneration. BioTime’s subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and therapeutic applications of stem cell technology in cancer, including the diagnostic product PanC-DxTM currently being developed for the detection of cancer in blood samples, therapeutic strategies using vascular progenitor cells engineered to destroy malignant tumors. ReCyte Therapeutics, Inc. is developing applications of BioTime’s proprietary induced pluripotent stem cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases. BioTime’s newest subsidiary, LifeMap Sciences, Inc., is developing an online database of the complex cell lineages arising from stem cells to guide basic research and to market BioTime’s research products. In addition to its stem cell products, BioTime develops blood plasma volume expanders, blood replacement solutions for hypothermic (low-temperature) surgery, and technology for use in surgery, emergency trauma treatment and other applications. BioTime’s lead product, Hextend, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements. Additional information about BioTime, ReCyte Therapeutics, Cell Cure, OrthoCyte, OncoCyte, BioTime Asia, LifeMap Sciences, and ESI can be found on the web at www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime’s Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://phx.corporate-ir.net/phoenix.zhtml?c=83805&p=irol-alerts

Advances in regenerative medicine spark skin cell banking startup

Regenerative Medicine Comments Off

Mar 222012

Weve heard of people freezing their eggs, blood and stem cells for use later on, but a health service startup is now enabling patients to freeze their own skin cells for potential future use in diagnostics, therapeutics and regenerative medicine techniques.

Next Healthcare Inc.s goal is to enable personalized healthcare by providing skin and stem cell banking directly to patients through their medical professional. Technologies that utilize human skin cells and stem cells are rapidly evolving, the company says on its website. These approaches may allow people to one day treat their diseases or conditions with their own cells.

Through their doctors, patients submit to Next Healthcare a skin and blood sample collected through a small punch biopsy. The company extracts skin cells from the tissue and stores them using cryopreservation, along with a component of the blood that contains stem cells.

Excerpt from:
Advances in regenerative medicine spark skin cell banking startup

Anatomy of Success: Genetic Research Develops Tools for Studying Diseases, Improving Regenerative Treatment

Regenerative Medicine Comments Off

Mar 202012

Newswise MANHATTAN, KAN. — Research from a Kansas State University professor may make it easier to recover after spinal cord injury or to study neurological disorders.

Mark Weiss, professor of anatomy and physiology, is researching genetic models for spinal cord injury or diseases such as Parkinson’s disease. He is developing technology that can advance cellular therapy and regenerative medicine — a type of research that can greatly improve animal and human health.

“We’re trying to build tools, trying to build models that will have broad applications,” Weiss said. “So if you’re interested in neural differentiation or if you’re interested in response after an injury, we’re trying to come up with cell lines that will teach us, help us to solve a medical mystery.”

Weiss’ research team has perfected a technique to use stem cells to study targeted genetic modifications. They are among a handful of laboratories in the world using these types of models for disease. The research is an important step in the field of functional genomics, which focuses on understanding the functions and roles of these genes in disease.

The researchers are creating several tools to study functional genomics. One such tool involves developing new ways to use fluorescent transporters, which make it easier to study proteins and their functions. These fluorescent transporters can be especially helpful when studying neurological disorders such as Parkinson’s disease, stroke and spinal cord injury.

“People who have spinal cord injury do not experience a lot of regeneration,” Weiss said. “It is one of the problems of the nervous system — it is not great at regenerating itself like other tissues.”

The researchers want to discover a way to help this regenerative process kick in. By studying signals from fluorescing cells, they can understand how neural stem cells are reactivated.

“We want to try and make these genetic markers, and then we can test different kinds of treatment to see how they assist in the regenerative process,” Weiss said.

Weiss’ stem cell research has appeared in two recent journals: Stem Cells and Development and the Journal of Assisted Reproduction and Genetics. His research has been funded by the National Institutes of Health and university funds, including the Johnson Cancer Research Center.

Weiss’ seven-member research team includes a visiting professor, two full-time researchers, a graduate student and three undergraduates. He has also been collaborating with researchers from the University of Kansas Medical Center.

See the rest here:
Anatomy of Success: Genetic Research Develops Tools for Studying Diseases, Improving Regenerative Treatment

To fix a heart, doctors train girl's body to grow new part

Regenerative Medicine Comments Off

Mar 202012

Four-year-old Angela Irizarry was born with a single pumping chamber in her heart, a potentially lethal defect. To fix the problem, Angela is growing a new blood vessel in her body in an experimental treatment that could advance the burgeoning field of regenerative medicine.

Doctors at Yale University here implanted in Angela’s chest in August a bioabsorbable tube that is designed to dissolve over time. The tube was seeded with cells, including stem cells, that had been harvested from Angela’s bone marrow. Since then, the doctors say, the tube has disappeared, leaving in its place a conduit produced by Angela’s cells that functions like a normal blood vessel.

“We’re making a blood vessel where there wasn’t one,” said Dr. Christopher Breuer, the Yale pediatric surgeon who led the 12-hour procedure to implant the device. “We’re inducing regeneration.”

Angela, who had little stamina before the operation, now has the energy of a regular kid. She is on several medications, but Breuer and her parents think she’ll be able to start school in the fall.

Scientists have long been captivated by the ability of animals such as salamanders and starfish to regrow body parts lost to injury. It was long assumed that developmental forces that create a human being in the womb are lost at birth. But recent advances in stem-cell research and tissue engineering suggest that regenerative forces can be reawakened with strategically implanted stem cells and other tissue.

This notion is fueling research at many academic laboratories and dozens of start-up companies where scientists are hoping to identify effective ways to treat maladies including heart muscle damaged from heart attacks, paralysis due to spinal cord injuries and poor-functioning kidneys and bladders.

Angela’s condition, known as hypoplastic left heart syndrome, affects some 3,000 newborns in the U.S. each year. With just one pumping chamber, or ventricle, instead of the usual two, the babies can’t deliver sufficient levels of oxygen to their organs and extremities, compromising their development and causing them to turn blue and suffer from a lack of energy. Without a surgical repair, says Breuer, 70 percent of them die before their first birthday.

Pediatric surgeons typically treat the condition with a series of operations called the Fontan procedure, designed to enable the heart to function without the missing ventricle. The last operation involves implanting a synthetic blood vessel made of Gore-Tex to reroute blood from the lower extremities directly to the lungs instead of through the heart. The device works, but it is prone to clotting, infection and in some cases, the need for additional surgery later in life as the child grows. The idea behind Breuer’s project is that a natural conduit with the biology of a normal blood vessel would grow with the child and avoid or significantly reduce complications associated with a synthetic tube.

Angela’s case “is a real milestone and broadly important for the field of tissue engineering,” said Robert Langer, a researcher at Massachusetts Institute of Technology and a regenerative-medicine pioneer who isn’t involved in the Yale initiative. “It gives you hope that when you combine cells with a scaffold and [put] them in the body, they will do the right thing.”

Angela’s heart defect was diagnosed in utero, when her mother Claudia was five months pregnant. She had her first operation when she was 5 days old, and another at 8 months. But her heart defect was taking a toll. She was shy, small for her age and lacked the stamina of a normal 3-year-old.

Here is the original post:
To fix a heart, doctors train girl's body to grow new part

Genetic research develops tools for studying diseases, improving regenerative treatment

Regenerative Medicine Comments Off

Mar 202012

ScienceDaily (Mar. 19, 2012) Research from a Kansas State University professor may make it easier to recover after spinal cord injury or to study neurological disorders.

The researchers want to discover a way to help this regenerative process kick in. By studying signals from fluorescing cells, they can understand how neural stem cells are reactivated.

“We want to try and make these genetic markers, and then we can test different kinds of treatment to see how they assist in the regenerative process,” Weiss said.

Go here to read the rest:
Genetic research develops tools for studying diseases, improving regenerative treatment

Biostem U.S., Corporation Continues Building Its Scientific and Medical Board of Advisors With Appointment of Leading ...

Regenerative Medicine Comments Off

Mar 202012

CLEARWATER, FL–(Marketwire -03/19/12)- Biostem U.S., Corporation (OTCQB: BOSM.PK – News) (Pinksheets: BOSM.PK – News) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine sciences sector, announced today the addition of Perinatologist Sanford M. Lederman, MD to its Scientific and Medical Board of Advisors (SAMBA).

As Chairman of the Department of Obstetrics and Gynecology at New York Methodist Hospital in Brooklyn, Dr. Lederman is consistently recognized by New Yorker Magazine’s list of “Top Doctors” in New York. A specialist in high-risk pregnancy issues, Dr. Lederman has authored a number of scientific papers and is a highly regarded public speaker. He adds a very important dimension to the Biostem Scientific and Medical Board of Advisors by bringing specialized knowledge regarding the potential use of stem cell applications for the health of women and children.

Biostem President Dwight Brunoehler said, “Dr. Lederman is one of the most highly respected Obstetric and Gynecological physicians in the country. Sandy and I have worked together very actively on stem cell projects for over 18 years, including setting up a cord blood stem cell national donation system where all expectant moms have a chance to donate their baby’s cord blood to benefit others.”

Dr. Lederman stated, “Biostem’s expansion plans mesh well with my personal interest in developing and advancing the use of non-controversial stem cells to improve the health of women and children. I have a particular interest in increasing the use of cord blood stem cells for in-utero transplant procedures, where stem cells are used to cure a potential life threatening disease such as sickle cell or thalassemia and other selective genetic disorders in a baby before it is even born.”

Prior to accepting his current position with New York Methodist Hospital, Dr. Lederman was Residency Program Director and Vice Chairman of the Department of Obstetrics and gynecology at Long Island College Hospital in Brooklyn. At various times, he has served as a partner at Brooklyn Women’s Health Care, President at Genetics East and Clinical Associate Professor at the State University of New York. He has served on the medical advisory board of several companies. He previously was Medical Director of Women’s Health USA and was a founding member of the Roger Freeman Perinatal Society.

A graduate of Hunter College in New York, he received his initial medical training at Universidad Autonoma de Guadalajara School of Medicine. His initial internship was at New York Medical College in the Bronx. During the course of his career, Dr. Lederman has served and studied in various capacities at Long Island College Hospital in the Bronx, North Shore University Hospital in New York, Kings County Medical Center in Brooklyn, Long Beach Memorial Medical Center in California and the University of California at Irvine.

About Biostem U.S., CorporationBiostem U.S., Corporation (OTCQB: BOSM.PK – News) is a fully reporting Nevada corporation with offices in Clearwater, Florida. Biostem is a technology licensing company with proprietary technology centered around providing hair re-growth using human stem cells. The company also intends to train and license selected physicians to provide Regenerative Cellular Therapy treatments to assist the body’s natural approach to healing tendons, ligaments, joints and muscle injuries by using the patient’s own stem cells. Biostem U.S. is seeking to expand its operations worldwide through licensing of its proprietary technology and acquisition of existing stem cell related facilities. The company’s goal is to operate in the international biotech market, focusing on the rapidly growing regenerative medicine field, using ethically sourced adult stem cells to improve the quality and longevity of life for all mankind.

More information on Biostem U.S., Corporation can be obtained through www.biostemus.com, or by calling Kerry D’Amato, Marketing Director at 727-446-5000.

Tengion to Host Conference Call to Provide a Business Update and Report Fourth Quarter 2011 Financial Results on March ...

Regenerative Medicine Comments Off

Mar 202012

WINSTON-SALEM, N.C., March 19, 2012 /PRNewswire/ — Tengion, Inc. (NASDAQ: TNGN – News), a leader in regenerative medicine, today announced it will host a conference call and live audio webcast on Monday, March 26, 2012, at 5:00 p.m. EDT to provide a business update and discuss its fourth quarter 2011 financial results.

To participate in the call, please dial 1-800-638-4930 (domestic) or 1-617-614-3944 (international) and reference access code 34844557.

The conference call can be accessed from the Investors section of the Company’s website or directly at http://edge.media-server.com/m/p/o4v89uyi/lan/en. The webcast will also be archived on the website.

About Tengion

Tengion, a clinical-stage regenerative medicine company, is focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ. Using its Organ Regeneration Platform, the Company creates neo-organs using a patient’s own cells, or autologous cells. Tengion’s proprietary product candidates harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues. The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. An initial clinical trial is ongoing for the Company’s lead product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company’s lead preclinical candidate is the Neo-Kidney Augment, which is designed to prevent or delay dialysis by increasing renal function in patients with advanced chronic kidney disease. Tengion has worldwide rights to its product candidates.

Excerpt from:
Tengion to Host Conference Call to Provide a Business Update and Report Fourth Quarter 2011 Financial Results on March …

Craig Venter | CIRM Spotlight on Genomics - A Step to Personalized Medicine - Video

Regenerative Medicine Comments Off

Mar 172012

16-03-2012 11:56 Craig Venter, president and founder of the J. Craig Venter Institute, spoke to the California Institute for Regenerative Medicine governing board on January 17th, 2012, about the future of personalized medicine in which genomics, the study of genes and their function, is applied to pinpoint specific treatments for patients.

See the rest here:
Craig Venter | CIRM Spotlight on Genomics – A Step to Personalized Medicine – Video

Bioheart and Ageless Partner to Advance Stem Cell Field With Laboratory Training Programs

Regenerative Medicine Comments Off

Mar 162012

SUNRISE, Fla., March 15, 2012 (GLOBE NEWSWIRE) — Bioheart, Inc. (BHRT.OB) announced today that it has successfully conducted a laboratory training course in partnership with the Ageless Regenerative Institute, an organization dedicated to the standardization of cell regenerative medicine. The attendees participated in hands on, in depth training in laboratory practices in stem cell science.

“We had students from all over the world attend this first course including physicians, laboratory technicians and students,” said Mike Tomas, Bioheart’s President and CEO. “Bioheart is pleased to be able to share our 13 years of experience in stem cell research and help expand this growing life science field.”

The course included cell culture techniques and quality control testing such as flow cytometry and gram stain. In addition, participants learned how to work in a cleanroom operating according to FDA cGMP standards, regulations used in the manufacture of pharmaceuticals, food and medical devices. Aseptic techniques were also taught as well as cleanroom gowning, environmental monitoring and maintenance.

Future courses are open to physicians, laboratory technicians and students. After graduating the course, attendees are prepared to pursue research and careers in the field of stem cells and regenerative medicine. For more information about the course, contact info@agelessregen.com.

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart’s goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient’s quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com.

About Ageless Regenerative Institute, LLC

The Ageless Regenerative Institute (ARI) is an organization dedicated to the standardization of cell regenerative medicine. The Institute promotes the development of evidence-based standards of excellence in the therapeutic use of adipose-derived stem cells through education, advocacy, and research. ARI has a highly experienced management team with experience in setting up full scale cGMP stem cell manufacturing facilities, stem cell product development & enhancement, developing point-of-care cell production systems, developing culture expanded stem cell production systems, FDA compliance, directing clinical & preclinical studies with multiple cell types for multiple indications, and more. ARI has successfully treated hundreds of patients utilizing these cellular therapies demonstrating both safety and efficacy. For more information about regenerative medicine please visit www.agelessregen.com.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “would,” “estimate,” or “continue” or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

See the rest here:
Bioheart and Ageless Partner to Advance Stem Cell Field With Laboratory Training Programs

BioCardia and Juventas Announce Phase II Development Program of JVS-100 Delivered With the Helical Infusion System to ...

Regenerative Medicine Comments Off

Mar 152012

SAN CARLOS, Calif.–(BUSINESS WIRE)–

BioCardia, a leading provider of cardiovascular catheter systems designed to deliver biologic therapies for cardiac regeneration and Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announced today that they will continue to work together to execute Juventas Phase II trial of JVS-100 for the treatment of heart failure.

The Phase II safety and efficacy study has been allowed by the Food and Drug Administration and enrollment is targeted to start in Q2 2012. The previous Phase I trial enrolled 17 NYHA Class III heart failure patients and showed promising safety and signals of clinical benefit to the patients treated.

“JVS-100 provides the potential for an off the shelf regenerative medicine therapeutic, with the potential to significantly enhance patients lives, states Peter Altman, Ph.D., BioCardias President & CEO. We are pleased to have the opportunity to continue to work with the Juventas team.

BioCardias Helical catheter performed well in our Phase I clinical trial and is an attractive delivery system for our targeted patient population, states Rahul Aras, Juventass President and CEO. It is a catheter system that is simple to use with a proven safety profile and we are excited to be working with it in our upcoming Phase II trial.

About BioCardia

BioCardia, Inc., headquartered in San Carlos, CA is a privately-held commercial medical technology company that has developed percutaneous delivery systems for biologics to treat cardiovascular disease. The company’s initial products are intended to provide a new therapeutic option for patients with heart failure and chronic myocardial ischemia.

About the Helical Infusion System

The Helical Infusion System is a CE Marked steerable two catheter system that enables delivery of biologic therapies to the heart muscle from within the chamber of the heart. It requires no external capital equipment and has an excellent clinical safety profile. The Helical Infusion System is commercially available in the European Union and is under Investigation in the United States in ongoing clinical trials.

About Juventas Therapeutics

Read the rest here:
BioCardia and Juventas Announce Phase II Development Program of JVS-100 Delivered With the Helical Infusion System to …

Cosmetic Regenerative Medicine - Video

Regenerative Medicine Comments Off

Mar 142012

13-03-2012 16:42 Hear Dr. Bowen talk about the exciting field of Regenerative Medicine. The type of regenerative medicine Dr. Bowen practices uses our own adult stem cells to achieve desired results.

Read the rest here:
Cosmetic Regenerative Medicine – Video

ACT Announces Filing of Definitive Proxy

Regenerative Medicine Comments Off

Mar 142012

MARLBOROUGH, Mass.–(BUSINESS WIRE)–

Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that on Monday, March 12 it filed with the Securities and Exchange Commission a proxy statement containing a shareholder proposal for a reverse split of its common stock.

The annual meeting of stockholders will be held on Thursday, April 26, at the Hyatt Regency Suites, Palm Springs, 285 N. Palm Canyon Dr.,Palm Springs,Calif.,92262, on Thursday,April 26,2012, at 9 a.m. PDT, to consider the following proposals: election of five directors, ratifying the appointment of the companys public accounting firm, and a proposal to effect a reverse stock split of the companys common stock, at a ratio between one-for-twenty and one-for-eighty, and to reduce the number of authorized shares of the companys common stock in the same proportion as the reverse split, with the exact ratio to be determined by the board of directors.

This reverse stock split, which should better align the companys capital structure with its stage of development, and an accompanying Nasdaq listing application, will represent a significant step toward creating long-term shareholder value and building ACT into a world-class player in the regenerative medicine space, said Gary Rabin, chairman and CEO of ACT. I hope that our stockholders understand how important it is to vote For the reverse stock split. A Nasdaq listing will enable us to significantly broaden our shareholder base and attract institutional ownership, a process that can build on itself to position the company on very firm financial footing over the long term.

Stockholders who have questions on how to vote or need assistance voting their shares should contact the companys proxy solicitor InvestorCom, Inc. toll-free at(877) 972-0090.

Further Information ACT has filed with the Securities and Exchange Commission (the SEC) and will furnish to stockholders of record on the record date for the annual meeting a definitive proxy statement in connection with the reverse stock split and other matters to be acted upon at the annual meeting. The company, Mr. Rabin and certain of its directors, executive officers and other members of management may, under SEC rules, be deemed participants in the solicitation of proxies from the companys stockholders with respect to the reverse stock split and the other matters to be acted upon at the annual meeting. INVESTORS AND STOCKHOLDERS ARE ADVISED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED REVERSE STOCK SPLIT AND OTHER IMPORTANT INFORMATION INCLUDING THOSE PERSONS WHO MAY BE DEEMED PARTICIPANTS IN THE SOLICITATION. Investors and stockholders may obtain a free copy of the definitive proxy statement, and other documents filed by us with the SEC, including the preliminary proxy statement, at the SECs web site at http://www.sec.gov. Free copies of the definitive proxy statement, and the Companys other filings with the SEC may also be obtained from the Company by directing a request to Advanced Cell Technology, Inc., 33 Locke Drive, Marlborough, Massachusetts 01752, Attention: Secretary.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words will, believes, plans, anticipates, expects, estimates, and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the companys periodic reports, including the report on Form 10-K for the year ended December 31, 2011. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Companys clinical trials will be successful.

Read the rest here:
ACT Announces Filing of Definitive Proxy

Advanced Cell Technology to Present at the 24th Annual ROTH Conference

Regenerative Medicine Comments Off

Mar 132012

MARLBOROUGH, Mass.–(BUSINESS WIRE)–

Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the companys chairman and CEO, Gary Rabin, will be presenting at Roth Capital Partners 24th Annual ROTH Conference, March 11-14.

Mr. Rabins presentation will take place on Wednesday, March 14, at 12:00PM PDT at the Ritz Carlton Laguna Niguel, Salon 2, in Dana Point, Calif. The presentation slide deck will be available on the Conference Presentations section of the ACT website and the webcast of the presentation will be available via the following link: http://wsw.com/webcast/roth26/actc.ob/.

Roth Capital Partners plans to host more than 400 growth companies at its 24th annual investment conference, March 11-14, including more than 130 healthcare companies in the biotechnology, healthcare services, medical device, and pharmaceutical sectors.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements

Older Entries Newer Entries

FireFox!	Start Your Own Web Hosting Company	Kids Furniture
Web Hosting	Advertise Here $10 a Month	Affordable web-hosting
Pierre Teilhard De Chardin

Organogenesis CEO Geoff MacKay Elected Chairman of MassBio Board of Directors

Tengion Announces Significant Advances in Neo-Urinary Conduit™ and Neo-Kidney Augment™ Programs

Synthetic pasta-like objects are major chemistry advances for regenerative medicine

'Noodle gels' or 'spaghetti highways' could become tools of regenerative medicine

Soon, noodle gels 'may become tools of regenerative medicine'

Stem Cells and Regenerative Medicine for Cardiac Care by Dr. Victor Dzau - Video

Regenerative Medicine Science - Video

BioTime CEO Michael D. West to Present at 2012 Maxim Group Growth Conference

Advances in regenerative medicine spark skin cell banking startup

Anatomy of Success: Genetic Research Develops Tools for Studying Diseases, Improving Regenerative Treatment

To fix a heart, doctors train girl's body to grow new part

Genetic research develops tools for studying diseases, improving regenerative treatment

Biostem U.S., Corporation Continues Building Its Scientific and Medical Board of Advisors With Appointment of Leading ...

Tengion to Host Conference Call to Provide a Business Update and Report Fourth Quarter 2011 Financial Results on March ...

Craig Venter | CIRM Spotlight on Genomics - A Step to Personalized Medicine - Video

Bioheart and Ageless Partner to Advance Stem Cell Field With Laboratory Training Programs

BioCardia and Juventas Announce Phase II Development Program of JVS-100 Delivered With the Helical Infusion System to ...

Cosmetic Regenerative Medicine - Video

ACT Announces Filing of Definitive Proxy

Advanced Cell Technology to Present at the 24th Annual ROTH Conference

Important Posts

Pages

Categories

Recent Posts

Subscribe to prometheism-pgroup

Important Posts

Pages

Categories

Recent Posts

Tags

Subscribe to prometheism-pgroup